Mobile

A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Update Il y a 4 ans
Reference: EUCTR2007-002725-74

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The proportion of patients achieving a PSA decline of >50% (PSA response) according to Prostate-Specific Antigen Working Group (PSAWG) criteria

Inclusion criteria

  • HRPC (Hormone refractory prostate cancer) refractory to androgen deprivation and Docetaxel based chemotherapy

Links